Drug Profile
Cannabidiol intravenous - Isosceles Pharmaceuticals
Alternative Names: IPI-201Latest Information Update: 26 May 2023
Price :
$50
*
At a glance
- Originator Isosceles Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Postoperative pain